Table 3 Demographic, laboratory, and disease-related variables in HIV-infected patients with normal TBS and low TBS
From: Trabecular bone scores in young HIV-infected men: a matched case-control study
Variables (N (%) or mean ± SD) | Normal TBS (< 1.31, N = 74) | Low TBS (≤1.31, N = 6) | P-value |
|---|---|---|---|
Demographic findings | |||
Age, years | 38.4 ± 8.7 | 37.7 ± 7.6 | 0.83 |
BMI (kg/m2) | 22.9 ± 2.8 | 23.4 ± 5.5 | 0.84 |
Currently smoking | 34 (45.9%) | 2 (33.3%) | 0.550 |
Alcohol ≥3 units/day | 3 (4.1%) | 0 (0%) | 0.615 |
Previous fracture | 8 (10.8%) | 2 (33.3%) | 0.109 |
Underlying disease | |||
Diabetes mellitus | 3 (4.1%) | 0 (0%) | 0.615 |
Hypertension | 4 (5.4%) | 0 (0%) | 0.559 |
Dyslipidemia | 8 (10.8%) | 0 (0%) | 0.395 |
Laboratory findings | |||
Total lymphocyte | 2921.7 ± 1481.3 | 2393.8 ± 660.5 | 0.39 |
Urea nitrogen (mg/dl) | 13.4 ± 3.5 | 10.9 ± 2.5 | 0.10 |
Creatinine (mg/dl) | 0.9 ± 0.1 | 0.77 ± 0.08 | 0.003 |
Calcium (mg/dl) | 9.1 ± 0.3 | 9.3 ± 0.2 | 0.21 |
Phosphorus (mg/dl) | 3.3 ± 0.5 | 3.6 ± 0.47 | 0.19 |
ESR (mm/h) | 9.3 ± 9.1 | 12.1 ± 6.8 | 0.46 |
Hemoglobin (g/dl) | 15.3 ± 1.0 | 14.6 ± 0.4 | 0.12 |
Platelet (103/μl) | 228 ± 40 | 227 ± 30 | 0.97 |
Alkaline phosphatase (U/l) | 65.2 ± 18.2 | 58.5 ± 14.8 | 0.38 |
25[OH]D (ng/ml) | 21.2 ± 8.2 | 20.4 ± 6.1 | 0.80 |
C-peptide (μg/ml) | 0.4 ± 0.2 | 0.23 ± 0.07 | 0.08 |
Osteocalcin (μg/ml) | 19.1 ± 8.6 | 16.2 ± 4.3 | 0.41 |
HIV-specific factors | |||
Duration since HIV diagnosis (days) | 2665.2 ± 1827.9 | 2101.2 ± 1704.1 | 0.47 |
Nadir CD4 T-cell counts (cells/μl) | 273.3 ± 158.2 | 360.0 ± 135.2 | 0.77 |
RNA level (copies/ml) | 151,420.4 ± 380,279.0 | 27,523.1 ± 54,226.9 | 0.37 |
Current CD4 count (cells/μl) | 668.2 ± 280.7 | 679.3 ± 130.0 | 0.92 |
Current proportion with plasma HIV-1 RNA levels < 40 copies/ml | 69 (93.2%) | 6 (100%) | 0.511 |
On ART | 73 (98.6%) | 5 (83.3%) | 0.02 |
NNRTI | 27 (36.5%) | 1 (16.7%) | |
Protease inhibitor | 27 (36.5%) | 1 (16.7%) | |
Integrase inhibitor | 18 (24.3%) | 3 (50%) | |
On TDF | 37 (50.0%) | 3 (50.0%) | 1.00 |
Duration of ART by regimen type, days | |||
NRTI | 1964.9 ± 1550.6 | 1097.7 ± 1156.1 | 0.18 |
NNRTI | 1304.5 ± 1217.0 | 570.0 ± 476.5 | 0.40 |
PI | 1234.5 ± 1479.9 | 870.6 ± 1195.8 | 0.59 |
Integrase inhibitor | 155.4 ± 425.8 | 181.5 ± 271.4 | 0.88 |
TDF | 671.2 ± 429.2 | 709.7 ± 226.9 | 0.89 |